MedTrace Logo

Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy

NCT05777824 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2023-10-11

No results posted yet for this study

Summary

To develop postoperative stratification treatment for patients who have received induction chemotherapy and immunotherapy in locally advanced head and neck cancers. Risk stratification is based on clinical characteristics and pathological responses. In order to achieve no inferior survival rate and a lower treatment-related toxicity rate than the standard treatment.

Conditions

Interventions

COMBINATION_PRODUCT

anti-PD-1 or PD-L1 antibody

immunotherapy maintenance with anti-PD-1 or PD-L1 antibody every three weeks for 13 cycles after radiotherapy

RADIATION

postoperative radiaotherapy

postoperative radiotherapy (60Gy or 50Gy)

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Junlin Yi, Doctor · National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2025-12-30
Completion
2027-12-30

Countries

  • China

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05777824 on ClinicalTrials.gov